Eucrisa gained approval based on two trials involving over 1,500 patients with mild-to-moderate eczema, showing the ointment was more effective than placebo in achieving clear or almost clear skin ...

These agents include the following: Pfizer’s Eucrisa is a first-in-class phosphodiesterase 4 (PDE4) inhibitor that was approved in the US and EU in 2016, but was subsequently withdrawn from the ...